ScripJiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US
ScripWho: Roche and Oxford BioTherapeutics What: The Swiss major has entered into a multi-year collaboration with OBT to develop first-in-class antibody-based therapeutics for the treatment of cancer.
ScripTaiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c
ScripBiopharmaceutical companies looking to raise money in 2025 can expect more of the same as what they experienced in 2024, according to market observers who were in San Francisco for the recent J.P. Mor